Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down – What’s Next?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $6.25, but opened at $5.60. Maravai LifeSciences shares last traded at $5.6880, with a volume of 683,238 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRVI. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Wells Fargo & Company increased their price objective on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, Wall Street Zen downgraded Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.83.

Maravai LifeSciences Stock Performance

The company has a current ratio of 5.91, a quick ratio of 4.96 and a debt-to-equity ratio of 0.72. The company’s fifty day moving average is $5.95 and its 200 day moving average is $4.37. The company has a market cap of $1.51 billion, a P/E ratio of -8.23 and a beta of 0.63.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The company had revenue of $65.84 million for the quarter, compared to analysts’ expectations of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. As a group, equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the transaction, the general counsel owned 360,767 shares in the company, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.49% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC lifted its position in Maravai LifeSciences by 1,463.1% in the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock valued at $841,000 after purchasing an additional 356,067 shares during the last quarter. Creative Planning boosted its stake in shares of Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company’s stock valued at $280,000 after purchasing an additional 38,450 shares during the period. Rhumbline Advisers grew its holdings in shares of Maravai LifeSciences by 20.3% in the second quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock worth $471,000 after purchasing an additional 32,940 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Maravai LifeSciences in the second quarter worth approximately $36,000. Finally, Invesco Ltd. increased its stake in shares of Maravai LifeSciences by 16.8% in the second quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock worth $680,000 after buying an additional 40,495 shares during the period. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.